Repros Therapeutics CEO Buys $29,211 in Stock (RPRX)
Repros Therapeutics (NASDAQ:RPRX) CEO Joseph Podolski bought 2,100 shares of Repros Therapeutics stock on the open market in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $13.91 per share, with a total value of $29,211.00. Following the completion of the purchase, the chief executive officer now directly owns 61,045 shares of the company’s stock, valued at approximately $849,136. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Repros Therapeutics (NASDAQ:RPRX) opened at 14.56 on Monday. Repros Therapeutics has a 52-week low of $12.61 and a 52-week high of $29.79. The stock’s 50-day moving average is $15.16 and its 200-day moving average is $16.81. The company’s market cap is $336.5 million.
Repros Therapeutics (NASDAQ:RPRX) last released its earnings data on Monday, August 11th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $0.01. On average, analysts predict that Repros Therapeutics will post $-1.53 earnings per share for the current fiscal year.
Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.